<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636608</url>
  </required_header>
  <id_info>
    <org_study_id>P15-709</org_study_id>
    <secondary_id>HU15-01</secondary_id>
    <nct_id>NCT02636608</nct_id>
  </id_info>
  <brief_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS</brief_title>
  <acronym>VERITAS</acronym>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IST GmbH, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to provide evidence of the effectiveness and obtain patient reported outcome
      (PRO) and work productivity data of the interferon-free regimen of Paritaprevir
      (PTV)/ritonavir (r) + Ombitasvir (OBV), ± Dasabuvir (DSV), ± Ribavirin in chronic hepatitis
      C virus infected participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The Percentage of Participants Achieving Sustained Virological Response 12 weeks Post-treatment (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantification 12 weeks after the last dose of study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Achieving Sustained Virological Response 24 weeks Post-treatment (SVR24)</measure>
    <time_frame>24 weeks after the last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA less than the lower limit of quantification 24 weeks after the last dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage Pattern of Treatment Regimen</measure>
    <time_frame>Up to post-treatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Case report form collection will evaluate the usage pattern of the treatment regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Direct Acting Antiviral (DAA) Dose taken in Relation to the Target Dose of DAA</measure>
    <time_frame>Up to post treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cumulative dose taken divided by target dose in percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Ribavirin (RBV) dose taken in relation to the target dose of RBV</measure>
    <time_frame>Up to post treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cumulative dose taken divided by target dose in percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Missed RBV Treatment Days in Relation to the Target Number of RBV Treatment Days</measure>
    <time_frame>Up to post treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Co-morbidities</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Concomitant Medications</measure>
    <time_frame>Day 0 to end of treatment, maximum week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concomitant medication used from the time when the decision is made to initiate treatment with the PTV/r+OBV±DSV±RBV until after the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Participants Quality of Life measured with the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Questionnaire</measure>
    <time_frame>Day 0 to post treatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Five items in the EQ-5D-5L questionnaire (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) are rated on 5 levels of severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Participants Workability measured with the Work Productivity and Activity Impairment (WPAI):Hepatitis C Questionnaire</measure>
    <time_frame>Day 0 to post treatment week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Questionnaire measures work time missed, work and non-work activity impairment due to a specified healthy problem during the past seven days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Participant Activation with the Patient Activation Measure (PAM-13) Questionnaire</measure>
    <time_frame>Day 0 to end of treatment, maximum week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>PAM 13 is a measure used to assess the patient knowledge, skill, and confidence for self-management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Support Program (PSP) Utilization and Satisfaction Assessment</measure>
    <time_frame>Up to post treatment week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Questionnaire to evaluate the frequency of use and satisfaction with the patient support program</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Genotype 1 (GT1) participants treated without Ribavirin (W12)</arm_group_label>
    <description>GT1 participants receiving PTV/r+OBV+DSV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1 (GT1) participants treated with Ribavirin (W12)</arm_group_label>
    <description>GT1 participants receiving PTV/r+OBV+DSV+RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1 (GT1) participants treated with Ribavirin (W24)</arm_group_label>
    <description>GT1 participants receiving PTV/r+OBV+DSV+RBV for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4 (GT4) participants treated with Ribavirin (W12)</arm_group_label>
    <description>GT4 participants receiving PTV/r+OBV+RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4 (GT4) participants treated with Ribavirin (W24)</arm_group_label>
    <description>GT4 participants receiving PTV/r+OBV+RBV for 24 weeks</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Hepatitis C (CHC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naïve or -experienced adult male or female patients with confirmed chronic
             hepatitis C (CHC), genotype 1 and 4, receiving combination therapy with the
             interferon-free Paritaprevir (PTV)/ritonavir (r) + Ombitasvir (OBV), ± Dasabuvir
             (DSV), ± Ribavirin (PTV/r+OBV±DSV±RBV) according to standard of care and in line with
             the current local label.

          -  If RBV is co-administered with the PTV/r+OBV±DSV±RBV, it has been prescribed in line
             with the current local label (with special attention to contraception requirements
             and contraindication during pregnancy).

          -  Patients must voluntarily sign and date Subject Information Form and Informed Consent
             Form prior to inclusion into the study.

          -  Patient must not be participating or intending to participate in a concurrent
             interventional therapeutic trial.

          -  Patient has been started on PTV/r+OBV±DSV±RBV therapy no more than one (1) month
             prior to the study enrollment.

        Exclusion Criteria: None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Béla Hunyady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Somogy Megyei Kaposi Mór Oktató Kórház</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krisztina Török, BA</last_name>
    <phone>+ 36 1 455 86 24</phone>
    <email>krisztina.torok@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariann Pataki, MD</last_name>
    <phone>+ 36 30 237 6050</phone>
    <email>mariann.pataki@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146069</name>
      <address>
        <city>Ajka</city>
        <zip>8400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146069, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146067</name>
      <address>
        <city>Bekescsaba</city>
        <zip>H-5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146067, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146055</name>
      <address>
        <city>Budapest</city>
        <zip>1111</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146055, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146057</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146057, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146058</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146058, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146059</name>
      <address>
        <city>Budapest</city>
        <zip>H-1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146059, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146063</name>
      <address>
        <city>Budapest</city>
        <zip>H-1025</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146063, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146065</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146065, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146068</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146068, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146061</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146061, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146056</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146056, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146062</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146062, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146066</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146066, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146064</name>
      <address>
        <city>Szombathely</city>
        <zip>H9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 146064, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 17, 2015</lastchanged_date>
  <firstreceived_date>December 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Observational Study</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Paritaprevir/r/Ombitasvir</keyword>
  <keyword>Dasabuvir</keyword>
  <keyword>Work Ability</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Fibrosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
